YD Bio (NASDAQ:YDES) Shares Gap Up - What's Next?

Key Points

• YD Bio (NASDAQ:YDES) gapped up pre-market from $7.43 to $7.79 but last traded at $7.41 and is down about 1.5%, trading below its 50‑day moving average of $8.84.
• Analysts' consensus remains negative with an average "Sell" rating; Weiss Ratings reiterated a "sell (d+)" while Wall Street Zen recently upgraded to "hold."
• Institutional interest rose modestly as Geode Capital Management increased its stake by 10% to 58,363 shares (about $711,000), and YD Bio develops DNA methylation‑based cancer detection and ophthalmologic technologies.

YD Bio Limited (NASDAQ:YDES - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $7.43, but opened at $7.79. YD Bio shares last traded at $7.41, with a volume of 5,606 shares changing hands.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on YDES shares. Weiss Ratings restated a "sell (d+)" rating on shares of YD Bio in a report on Monday, December 29th. Wall Street Zen raised shares of YD Bio from a "sell" rating to a "hold" rating in a research report on Saturday, February 28th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, YD Bio currently has an average rating of "Sell".

YD Bio Stock Down 1.5%

The company has a 50-day moving average price of $8.84.

Institutional Investors Weigh In On YD Bio

A hedge fund recently raised its stake in YD Bio stock. Geode Capital Management LLC grew its position in YD Bio Limited (NASDAQ:YDES - Free Report) by 10.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 58,363 shares of the biotechnology company's stock after purchasing an additional 5,292 shares during the period. Geode Capital Management LLC owned about 0.08% of YD Bio worth $711,000 as of its most recent filing with the SEC.

About YD Bio

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.